9 June 2022

Avance Clinical Announces at BIO 2022: Expansion Across Australia and New Zealand – New Offices and Double Growth

Sydney, Australia

Avance Clinical, the largest premium Australian Contract Research Organization (CRO) for international biotechs, has opened new offices in Sydney and Melbourne, with further expansions planned, and increased clinical staff numbers across the region to support double growth figures.

The Avance Clinical senior management team attending BIO 2022 will make the announcement at their booth #4907. The team at BIO includes Yvonne Lungershausen, CEO, Liahna Toy, Head of Business Development, and Ben Edwards, Chief Strategy Officer who are all taking meetings during the conference.

Avance Clinical’s CEO Yvonne Lungershausen said:

Australia and New Zealand are the locations of choice for international biotechs conducting early phase clinical trials. The demand is strong and increasing so we are growing to accommodate.

The world’s most attractive rebate on clinical trial spend as well as the no-IND requirement puts Australia in the lead for early stage research.

Australia is known for high-quality clinical data and significant patient populations across key therapeutic areas including oncology, dermatology, cardiology, CNS and infectious diseases.”

Avance Clinical recently secured a significant investment from global private equity firm, The Riverside Company (Riverside), to support further regional and global expansion. The investment values the company in excess of $200m.

“With the support of Riverside and its powerful global footprint and deep healthcare experience, Avance Clinical will execute on its regional and international expansion plans organically and via acquisitions,” said Lungershausen.

Avance Clinical is the Australian-owned CRO that provides global regulatory standard clinical research services across all phases to the local and international biopharma industry.

The company is also accredited as a gene technology CRO under the Office of the Gene Technology Regulator (OGTR) which has allowed it to expand into clinical trials for vaccines and GMO therapies.

“We have shown, with our high growth and industry-leading repeat business rates that our focus on gold standard technology paired with solution-orientated clinical experts is the mix our biopharma clients require in this fast-moving, competitive and high-stakes sector,” said Lungershausen.

Related Articles